Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25724221 | 0.81 | MAPT (0.38) | MAPTALDH1A1HTT | |
| SCHEMBL25724223 | 0.80 | MAPT (0.33) | MAPTALDH1A1HTT | |
| SCHEMBL18133834 | 0.77 | MAPT (0.43) | MAPTTGFBR1ALDH1A1HTT | |
| SCHEMBL18408609 | 0.77 | — | — | |
| SCHEMBL20970306 | 0.76 | — | — | |
| SCHEMBL17030767 | 0.73 | MAPT (0.58) | MAPTALDH1A1HTT | |
| SCHEMBL21734001 | 0.72 | NOS1 (0.32) | — | |
| SCHEMBL19115364 | 0.71 | MAPT (0.51) | MAPTTGFBR1ALDH1A1HTT | |
| SCHEMBL25703151 | 0.70 | MAPT (0.36) | MAPTALDH1A1HTT | |
| SCHEMBL18408663 | 0.70 | MAPT (0.34) | MAPTTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | ARAXES PHARMA LLC (US) | 2020-11-03 | — | — | US | disclosed |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | MAPT 258/4885TGFBR1 1550/4885ALDH1A1 4018/4885 |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | MAPT 258/4885TGFBR1 1550/4885ALDH1A1 4018/4885 |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | NRAS, KRAS, HRAS | MAPT 4773/4885TGFBR1 4749/4885ALDH1A1 4436/4885 |
| US-10975071-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | MAPT 185/4885TGFBR1 1160/4885ALDH1A1 3235/4885 |
| US-20190092767-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | MAPT 185/4885TGFBR1 1160/4885ALDH1A1 3235/4885 |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | NRAS, KRAS, HRAS | MAPT 4801/4885TGFBR1 4429/4885ALDH1A1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.